The European Commission has approved olaparib (Lynparza) as a single agent for the maintenance treatment of adult patients with advanced BRCA1/2
-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response (PR) following first-line platinum-based chemotherapy.1
The approval is based on findings from the double-blind, phase III SOLO-1 trial, in which maintenance olaparib led to a 70% reduction in the risk of disease progression or death compared with placebo in patients with BRCA
-mutant advanced ovarian cancer after completing frontline platinum-based chemotherapy (HR, 0.30; 95% CI, 0.23-0.41; P
The FDA approved olaparib for this indication in December 2018.
... to read the full story